CDH2 and cancer: Epithelial-mesenchymal transition (EMT) is a genetic program aberrantly activated in various cancers that is characterized by the loss of cell-cell adhesion protein E-cadherin and the acquisition of mesenchymal biomarkers such as N-cadherin, Vimentin and mmp2 [31–34].